🩸Final Questions on Myelofibrosis! Swipe to see the answers and their explanations.

Stay tuned for our next question series on Chronic Myelomonocytic Leukemia (CMML)!

#Myelofibrosis #MF #HemeHub #Hematology #HemOnc #MyeloidNeoplasms #BoneMarrowFibrosis #Anemia #Momelotinib #BloodDisorders #HEMEHUB

🩸 This Month on HemeHub: Chronic Myelomonocytic Leukemia (CMML)

Join us as we explore disease biology & pathogenesis, diagnosis, prognostic scoring, and treatment strategies in Chronic Myelomonocytic Leukemia.

#CMML #HemeHub #Hematology #HemOnc #MyeloidNeoplasms #BloodDisorders #HEMEHUB

A Call for Changes in Drug Development in Higher-Risk MDS Researchers assert that greater emphasis should be placed on biological classification over disease risk status alone in MDS clinical trials.

Recent failures in Phase 3 trials for high-risk #MDS necessitate a shift in drug development. Future strategies must prioritize novel combinations and distinct molecular targeting beyond hypomethylating agents.

Read the review: https://bit.ly/4uQnRoi

#HemOnc #ClinicalTrials

SAARC Region Shows Increasing Burden in Hematologic Malignancy Incidence and Mortality Researchers determined countries in the SAARC region demonstrate an increasing burden related to hematologic malignancies.

SAARC nations account for 9.3% of global cancer incidence but 12% of mortality. Elevated mortality-to-incidence ratios (0.65 vs 0.49 globally) indicate critical gaps in #hematologic care.

Read the review: https://bit.ly/4t5Zh1b

#cancerMortality #HemOnc

🩸🔍Today’s question!

Swipe to see the answer and its explanation!

#Hematology #Myelofibrosis #MPN #MyeloproliferativeNeoplasms #Ruxolitinib #Immunotherapy #NKCells #CellTherapy #HemOnc #Oncology #BloodDisorders #MedEd #MedicalEducation #HEMEHUB

🩸 Further insights into anemia management strategies in Myelofibrosis

#Hematology #Myelofibrosis #Anemia #MyeloproliferativeNeoplasms #MPN #BloodDisorders #HemOnc #Oncology #MedEd #MedicalEducation #BoneMarrow #IronOverload #Thrombosis #HEMEHUB

Understanding CHIP and CCUS With Lachelle D. Weeks, MD, PhD Lachelle D. Weeks, MD, PhD elucidates the complex and still-emerging field of clonal hematopoiesis, specifically regarding clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia o...

Dr Weeks discusses a relatively new area of research in #hematologyOncology: CHIP and CCUS.

https://bit.ly/4bDvNAH

#HemOnc

#Jacksonville! Join Drs. Advani Pooja, Julio Chavez, Bruna Pellini, Hani Babiker, and more, for practice-changing clinical data and expert recommendations to optimize outcomes for patients with hematologic malignancies. Register NOW: binaytara.org/projects/con... #CMEConference #Binaytara #HemOnc

Long-Distance Endurance Running May Impact Red Blood Cell Aging Researchers determined prolonged endurance running may impact RBCs, with signs associated with accelerated RBC aging observed with ultra-running.

Prolonged endurance #running may impact #redBloodCells, with signs associated with accelerated #RBC aging observed with ultra-running. Published in @bloodjournals.hematology.org.

https://bit.ly/4dmpsfg

#HemOnc

We're thrilled to be an official media partner for #EBMT26, and we can't wait to be on-site once again, filming our expert video interviews! 🎥🩸

Interested in joining us there or attending virtually?

Click here to register now:
➡️ buff.ly/bWxuru2

#BMTsm #HemOnc #ImmunoOnc @theebmt.bsky.social

🩸Facts about Multiple Myeloma:

Myeloma Biology and Microenvironment

#MultipleMyeloma #Hematology #NKcells #Cytogenetics #HEMEHUB #TP53 #NFkB #Hyperdiploidy #t1114 #del17p #HemOnc #MedEd

Official Registration to EBMT 2026 Sign up to attend the 52nd Annual Meeting of the EBMT in-person in Madrid or virtually. Get the best rate by registering before the Early Bird deadline on 19 January 2026.

Want to find out about the latest updates and advances in transplantation and cellular therapy?🩸

Then you won't want to miss the 52nd Annual Meeting of the EBMT taking place 22–25 March in Madrid, Spain, & online.🇪🇸💻

Register here:
➡️ buff.ly/0fBo0ka

#EBMT26 #HemOnc #BMTsm @theebmt.bsky.social

🩸Facts about Multiple Myeloma:

Frontline Integration

#MultipleMyeloma #Hematology #BispecificAntibodies #StemCellTransplant #ASCT #BsAbs #MRD #ClinicalTrials #Elranatamab #Teclistamab #MajesTEC4 #MajesTEC5 #HemOnc #HEMEHUB

Join us at the CME/MOC/ACPE-accredited Best of Hematology and Breast Cancer 2026, Boise: binaytara.org/projects/con... #HemOnc #CMEConference #Medsky

🩸 Additional insights on adverse events and management in Multiple Myeloma

#MultipleMyeloma #BCMA #GPRC5D #BispecificAntibodies #BsAbs #Immunotherapy #PlasmaCells #IVIG #Oncology #HemOnc #Hematology #ClinicalTrials #MajesTEC3 #HEMEHUB

Join us at the CME/MOC/ACPE-accredited Best of Hematology and Breast Cancer 2026, Boise: binaytara.org/projects/con... #HemOnc #CMEConference #Medsky

Join us at the CME/MOC/ACPE-accredited Best of Hematology and Breast Cancer Conference 2026 in Baton Rouge, LA: binaytara.org/projects/con... #HemOnc #CMEConference #Medsky

Join us at the CME/MOC/ACPE-accredited Dogmas & Controversies in Hematologic Malignancies: Los Angeles 2026: binaytara.org/projects/con... #CMEConference #Medsky #HemOnc

Real-World Use of Efanesoctocog Alfa Shows Benefit in Severe Hemophilia A Efanesoctocog alfa improves hemostasis, reduces bleeding, and enhances quality of life for patients with severe hemophilia A, including those previously excluded from trials.

Efanesoctocog alfa has been successfully integrated into clinical practice for treating severe #hemophilia A, including patients previously excluded from trials, such as those with FVIII inhibitors or prior emicizumab use. From @rarediseaseadvisor.bsky.social.

https://bit.ly/4k5pkCc

#hemonc

🤝Honored to partner with the United Porphyrias Association to advance education, awareness, and support for patients living with rare porphyrias. Looking forward to fostering a meaningful impact together.

🌍Stay connected: hemehub.org

#RareDisease #UPA #Porphyria #HemOnc #MedEd #Hematology #HemeHub

Join us at the CME/MOC/ACPE-accredited Best of Hematology and Breast Cancer 2026, Boise: buff.ly/9jFgCuq #HemOnc #CMEConference #Medsky

CNI vs Belimumab for Lupus Nephritis May Carry Higher Cancer Risk Investigators compared the risk of cancer onset in patients with lupus nephritis treatedwith calcineurin inhibitors vs belimumab.

“These findings align with prior mechanistic research demonstrating increased CNI-related #cancerrisk and represents novel comparative safety data between these treatment modalities,” @jeffsparks.bsky.social of @harvardmed.bsky.social wrote.

https://bit.ly/4bqSrhm

#HemOnc

Join us at the CME/MOC/ACPE-accredited Best of Hematology and Breast Cancer Conference 2026 in Baton Rouge, LA: binaytara.org/projects/con... #HemOnc #CMEConference #Medsky

Just one week to go until #CART26 kicks off in Palma de Mallorca, Spain, and online!🇪🇸 💻

Hear from the meeting chair, Annalisa Ruggeri, who encourages you to register for this hybrid meeting:
🎥 buff.ly/poXdp9x

Register here:
➡️ buff.ly/LMXQ0qU..

#CARTCell #ImmunoOnc #HemOnc @theebmt.bsky.social

🩸🔬Today's question!

See the answer and explanation on the next slide.

#MultipleMyeloma #NDMM #AutologousStemCellTransplant #ASCT #VRd #GMMGHD7 #MRDNegativity #ClinicalTrials #Hematology #HemOnc #MedEd

🩸Facts about Multiple Myeloma:

Bispecific Antibodies (BsAbs) – Mechanism and Approval

#MultipleMyeloma #RRMM #Hematology #HemOnc #BispecificAntibodies #BsAbs #Immunotherapy #CD3 #BCMA #Teclistamab #Elranatamab #Linvoseltamab #MedEd

Join us at the CME/MOC/ACPE-accredited Dogmas & Controversies in Hematologic Malignancies: Los Angeles 2026: binaytara.org/projects/con... #CMEConference #Medsky #HemOnc

EnzySystem Shows Promising Results in Hemophilia Testing Patients favored using the system at home, especially for self-monitoring, while healthcare professionals supported both home and clinic use.

A new point-of-care platform is gaining attention as a promising tool to improve #coagulation testing for people with #hemophilia A. From @rarediseaseadvisor.bsky.social.

https://bit.ly/462BmXm

#HemOnc

🩸Proud to announce our partnership with Texas Oncology.

🤝🩺Together, we aim to advance education in #hematology and #oncology, support meaningful learning for clinicians, and ultimately improve clinical outcomes for patients.

🌍Stay connected: hemehub.org

#HemOnc #BloodDisorders #MedEd #HemeHub

Patients With Terminal Blood Cancer Stress Need for Transfusion Access in Hospice Care, Survey Finds Survey results showed patients with hematologic cancers eligible for hospice care prioritize access to transfusion over other services.

Patients with #bloodcancer eligible for #hospice care emphasize the importance of access to #transfusion over other services. Published in @jamanetworkopen.com.

https://bit.ly/4k6hl8d

#HemOnc